Cedrik M. Britten MD

Dr. Cedrik M. Britten is the head of Cell Therapy in the Immuno-Oncology and Combinations Unit at GlaxoSmithKline. Dr. Britten is renowned for his work on biomarkers, and his development of frameworks for personalized medicine approaches and technology commercialization. At GSK, his group’s focus is on developing novel immunotherapies involving engineered immune cells. Dr. Britten is a member of CRI’s Cancer Immunotherapy Consortium (CIC) Steering Committee.